company mission
PharmatrophiX's mission looks flat across the evidence we have. In both the February 27, 2015 and April 30, 2017 snapshots, the company says the same core thing: it is building disease-modifying small-molecule drugs aimed at mechanisms behind neurodegenerative and other disorders. The operating model also stays fixed. In both statements, PharmatrophiX describes itself as a virtual biotech and treats that structure as a practical choice to keep overhead low while still hitting development milestones. That is not a philosophical shift, it is the same business logic repeated. What changed is basically nothing we can defend from these two entries alone. The wording is effectively identical, so the clean read is continuity rather than evolution. Evidence is thin, though: we only have two website snapshots over a little more than two years, and both appear to restate the same positioning rather than update it.